XYZ-REALITY
16.4.2024 14:02:02 CEST | Business Wire | Press release
XYZ Reality, the leading engineering grade augmented reality (AR) platform for data center and mission critical construction, is proud to announce the appointment of data center industry veterans Christian Belady and Brian Mattson as Strategic Advisors. With their extensive experience and innovative vision, they will help guide XYZ Reality in enhancing its data center construction solution and product roadmap.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416398782/en/
Christian Belady (Photo: Business Wire)
Christian Belady, recognized as one of the "5 People who changed the data center" industry, brings a wealth of expertise in managing data center and infrastructure development at a global scale. Formerly Vice President and Distinguished Engineer at Microsoft, Belady developed one of the largest data center footprints in the world. Notably, during his tenure at Hewlett Packard, he was the innovator behind the Power Usage Effectiveness (PUE) metric. His expertise will prove invaluable to XYZ Reality's mission of building it right first time, offering crucial support in product development and sharing invaluable insights and expertise garnered from years of experience in the data center industry.
“I am thrilled to join XYZ Reality as a Strategic Advisor,” said Christian Belady. “At a time when speed to market is paramount, the company’s approach and cutting-edge technology to transforming data center construction and delivery is impressive, and I am eager to contribute to its success with our combined experience and knowledge.”
Brian Mattson brings over 40 years of experience leading large-scale global engineering and construction programs in the semiconductor and data center industries. Prior to joining XYZ Reality, Mattson served in leadership roles at Google, NTT Global Data Centers Americas, and Microsoft. His leadership at Google and Microsoft in global construction and infrastructure supply chain will contribute significantly to XYZ Reality’s growth.
"We are delighted to welcome Christian Belady and Brian Mattson to XYZ Reality as Strategic Advisors," said David Mitchell, Founder & CEO of XYZ Reality. "Their passion, expertise and innovative track record are crucial as we transform the data center industry with our Platform. This collaboration will further enhance our real-time project controls, enabling a proactive approach to construction. Their insights in the mission critical space will streamline processes and boost efficiency as we pioneer proactive solutions in this field.”
Notes to Editor
XYZ Reality is a leading developer of construction technology solutions that give owners and contractors an accurate and objective way to manage and deliver projects. Combining its Engineering Grade AR™ technology and comprehensive Project Controls solution, XYZ gives construction teams the ability to accurately build from holograms of 3D models, and proactively manage their projects with objective real-time insights. This is a revolutionary move away from a reliance on 2D drawings and subjective, out of date data, towards a future where accuracy means each project is built right, first time. The largest developers have implemented XYZ on projects totaling over $10 billion. XYZ is headquartered in London, England with offices around the globe. For more information, visit www.xyzreality.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416398782/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom